YelenaYJanjigianMD

Gastrointestinal Cancer

Chief, GI Oncology Service Memorial Sloan Kettering Cancer Center

Overview of Dr. Janjigian

Dr. Yelena Janjigian is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from New York University Grossman School of Medicine and has been in practice 14 years. Dr. Janjigian accepts several types of health insurance, listed below. She is one of 464 doctors at Memorial Sloan Kettering Cancer Center and one of 88 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
Memorial Sloan Kettering Cancer Center New York
1275 York Avenue
New York, NY 10021
Book by Phone+1(901) 509-9141
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
NYU Grossman School of MedicineResidency, Internal Medicine, 2003 - 2006
New York University School of MedicineClass of 2003

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2006 - 2025
NJ State Medical License 2019 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma Start of enrollment: 2006 Oct 23
Completed
Phase 2
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery Start of enrollment: 2009 Sep 01
Completed
Phase 2
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer Start of enrollment: 2012 Mar 01
Completed
Phase 2
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 2
Nintedanib in Patients With Advanced Esophagogastric Cancer Start of enrollment: 2014 Sep 04
Completed
Phase 2
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer Start of enrollment: 2016 Mar 18
Terminated
Phase 2
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer Start of enrollment: 2016 Nov 03
Completed
Phase 2
Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors Start of enrollment: 2019 Feb 20
Active, not recruiting
Early Phase 1
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer Start of enrollment: 2021 Feb 11
Active, not recruiting
Phase 2
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection Start of enrollment: 2020 Aug 10
Terminated
Phase 2
Roles: Contact, Principal Investigator
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer Start of enrollment: 2024 Feb 01
Recruiting
Phase 2
Roles: Contact, Principal Investigator
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer Start of enrollment: 2024 Feb 01
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer.
Samuel L Cytryn, Neeta Pandit-Taskar, Melissa A Lumish, Steven B Maron, Ping Gu, Geoffrey Y Ku, Joanne F Chou, Marinela Capanu, Ariel Antoine, Diane Loegel, Lara Feder...> ;Journal of Nuclear Medicine. 2024 Mar 21
Patient metabolic profile defined by liver and muscleF-FDG PET avidity is independently associated with overall survival in gastric cancer.
Vitiello, G., Gerardo A Vitiello, Vetri Sudar Jayaprakasam, Laura H Tang, Mark A Schattner, Yelena Y Janjigian, Geoffrey Y Ku, Steven B Maron, Heiko Schoder, Steven M ...> ;Gastric Cancer. 2024 May 1
Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma.
Cameron N Fick, Elizabeth G Dunne, Smita Sihag, Daniela Molena, Samuel L Cytryn, Yelena Y Janjigian, Abraham J Wu, Stephanie G Worrell, Wayne L Hofstetter, David R Jon...> ;The Annals of Thoracic Surgery. 2024 Feb 24
1 citations
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023.
Yuko Kitagawa, Satoru Matsuda, Takuji Gotoda, Ken Kato, Bas Wijnhoven, Florian Lordick, Pradeep Bhandari, Hirofumi Kawakubo, Yasuhiro Kodera, Masanori Terashima, Kei M...> ;Gastric Cancer. 2024 May 1
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 ...
Janjigian, Y., Ajani, J., Moehler, M., Shen, L., Garrido, M., Gallardo, C., Wyrwicz, L., Yamaguchi, K., Cleary, J., Elimova, E., Karamouzis, M., Bruges, R., Skoczylas,...> ;Journal of Clinical Oncology. 2024 Feb 21
3 citations
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre...
Shitara, K., Rha, S., Wyrwicz, L., Oshima, T., Karaseva, N., Osipov, M., Yasui, H., Yabusaki, H., Afanasyev, S., Park, Y., Al-Batran, S., Yoshikawa, T., Yanez, P., Dib...> ;The Lancet. Oncology. 2024 Feb 1
17 citations
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 ...
Yelena Y Janjigian, Akihito Kawazoe, Yuxian Bai, Jianming Xu, Sara Lonardi, Jean Phillipe Metges, Patricio Yanez, Lucjan S Wyrwicz, Lin Shen, Yuriy Ostapenko, Mehmet B...> ;Lancet. 2023 Dec 9
3 citations
Impact ofinfection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors.
Patrick T Magahis, Steven B Maron, Darren Cowzer, Stephanie King, Mark Schattner, Yelena Janjigian, David Faleck, Monika Laszkowska> ;Journal for Immunotherapy of Cancer. 2023 Oct 1
2 citations
Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade.
Emily C Harrold, Michael B Foote, Benoit Rousseau, Henry Walch, Yelena Kemel, Allison L Richards, Fergus Keane, Andrea Cercek, Rona Yaeger, Dana Rathkopf, Neil H Segal...> ;Nature Medicine. 2023 Oct 1
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Ad...
Markus Moehler, Hong Xiao, Steven I Blum, Elena Elimova, David Cella, Kohei Shitara, Jaffer A Ajani, Yelena Y Janjigian, Marcelo Garrido, Lin Shen, Kensei Yamaguchi, T...> ;Journal of Clinical Oncology. 2023 Dec 10
1 citations
Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer.
Melissa A Lumish, Henry Walch, Steven B Maron, Walid Chatila, Yelena Kemel, Anna Maio, Geoffrey Y Ku, David H Ilson, Elizabeth Won, Jia Li, Smita S Joshi, Ping Gu, Mar...> ;Journal of the National Cancer Institute. 2024 Feb 8
3 citations
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre,...
Samuel L Cytryn, Ryan H Moy, Darren Cowzer, Ronak H Shah, Joanne F Chou, Smita S Joshi, Geoffrey Y Ku, Steven B Maron, Avni Desai, Jessica Yang, Ryan Sugarman, Devika ...> ;The Lancet. Oncology. 2023 Oct 1
Prognostic value of circumferential radial margin involvement in esophagectomy for esophageal cancer: a case series.
Thomas Boerner, Rebecca Carr, Meier Hsu, Kay See Tan, Carlie Sigel, Laura Tang, Caitlin Harrington, Geoffrey Y Ku, David H Ilson, Yelena Y Janjigian, Abraham J Wu, Smi...> ;International Journal of Surgery. 2023 Nov 1
1 citations
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.
Steven B Maron, Walid Chatila, Henry Walch, Joanne F Chou, Nicholas Ceglia, Ryan Ptashkin, Richard Kinh Gian Do, Viktoriya Paroder, Neeta Pandit-Taskar, Jason S Lewis,...> ;Clinical Cancer Research. 2023 Sep 15
4 citations
Perioperative versus total neoadjuvant chemotherapy in gastric cancer.
Jessica Yang, Megan Greally, Vivian E Strong, Daniel G Coit, Joanne F Chou, Marinela Capanu, Steven B Maron, David P Kelsen, David H Ilson, Yelena Y Janjigian, Geoffre...> ;Journal of Gastrointestinal Oncology. 2023 Jun 30
9 citations
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a...
Eric Van Cutsem, Maria di Bartolomeo, Elizabeth Smyth, Ian Chau, Haeseong Park, Salvatore Siena, Sara Lonardi, Zev A Wainberg, Jaffer Ajani, Joseph Chao, Yelena Janjig...> ;The Lancet. Oncology. 2023 Jul 1
4 citations
Management of immune-related cutaneous adverse events with dupilumab.
Alyce Mei-Shiuan Kuo, Stephanie Gu, Joseph Stoll, Andrea P Moy, Stephen W Dusza, Allison Gordon, Elena C Haliasos, Yelena Janjigian, Lukas Kraehenbuehl, Elizabeth A Qu...> ;Journal for Immunotherapy of Cancer. 2023 Jun 1
1 citations
HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers.
Yelena Y Janjigian, Cytryn, S.> ;Journal of the National Comprehensive Cancer Network. 2023 Apr 1
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic can...
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tian...> ;Future Oncology. 2023 Apr 1
2 citations
Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas.
S J Klempner, Y Y Janjigian, Z A Wainberg> ;ESMO Open. 2023 Apr 1
Durvalumab and PET-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma: A Phase Ib/II Study.
Darren Cowzer, Abraham Jing-Ching Wu, Smita Sihag, Henry S Walch, Bernard J Park, David R Jones, Ping Gu, Steven B Maron, Ryan Sugarman, Sree Bhavani Chalasani, Marina...> ;Annals of Surgery. 2023 Sep 1
1 citations
Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers.
Bill H Diplas, Ryan Ptashkin, Joanne F Chou, Shalom Sabwa, Michael B Foote, Benoit Rousseau, Guillem Argilés, James Robert White, Caitlin M Stewart, Kelly Bolton, Sree...> ;JAMA Network Open. 2023 Feb 1
Waiting to Operate: The Risk of Salvage Esophagectomy.
Thomas Boerner, Caitlin Harrington, Kay See Tan, Prasad S Adusumilli, Manjit S Bains, Matthew J Bott, Robert J Downey, James Huang, David H Ilson, James M Isbell, Yele...> ;Annals of Surgery. 2023 May 1
1 citations
Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting.
Zev A Wainberg, Jipan Xie, Adriana Valderrama, Lei Yin, Shujing Zhang, Chie-Schin Shih, Pooja Bhagia, Qianqian Gu, Kohei Shitara, Yelena Y Janjigian, Josep Tabernero> ;Clinical Cancer Research. 2023 Apr 3
32 citations
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Manish A Shah, Erin B Kennedy, Ashley E Alarcon-Rozas, Thierry Alcindor, Angela N Bartley, Aubrey Belk Malowany, Nishin A Bhadkamkar, Dana C Deighton, Yelena Janjigian...> ;Journal of Clinical Oncology. 2023 Mar 1
Join now to see all

Journal Articles

Indications for Total Gastrectomy in CDH1 Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies
Sam S Yoon, Yelena Janjigian, Daniel G Coit, Zsofia K Stadler, Vivian E Strong, JAMA Surgery
YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics
Emmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences

Lectures

Biomarkers to Guide Surveillance and Adjuvant Therapy of Early-Stage Disease
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
Biomarkers for Better Treatment and Patient Selection
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Checkpoint Blockade in Esophagogastric Cancer
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Authored Content

Combination Therapies: The Wave of the FutureJanuary 2019
Checkpoint Blockade in Esophagogastric CancerJune 2018

Press Mentions

Agenus (AGEN) Q1 2023 Earnings Call TranscriptMay 9th, 2023
Transcenta to Present Two Clinical Trial Progress at ASCO 2023May 8th, 2023
Zolbetuximab Improves Survival in Gastric CancerMarch 26th, 2023
Join now to see all

Hospital Affiliations

Memorial Sloan Kettering Cancer CenterNew York, New York
Memorial Hospital for Cancer and allied DiseasesBasking Ridge, New Jersey

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Texas BlueChoice
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment